Johnson & Johnson Expects 2024 Reported Sales Of $88.4B–$88.8B Compared To Prior Guidance Of $88.0B–$88.4B And Consensus Of $88.51B
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has updated its 2024 sales guidance to $88.4B–$88.8B, slightly above its previous guidance and close to consensus estimates. The company also provided adjusted operational EPS figures, indicating a slight decrease compared to prior guidance.
October 15, 2024 | 10:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson has increased its 2024 sales guidance to $88.4B–$88.8B, slightly above its previous guidance and close to consensus estimates. Adjusted operational EPS figures show a slight decrease compared to prior guidance.
The increase in sales guidance suggests a positive outlook for Johnson & Johnson's revenue, which is likely to have a positive impact on the stock price. However, the slight decrease in adjusted EPS may temper investor enthusiasm, but overall, the news is more positive than negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100